Analysts expect that Zymeworks Inc (NYSE:ZYME) will announce earnings of ($0.64) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Zymeworks’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.39). Zymeworks reported earnings of ($0.59) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 8.5%. The company is expected to issue its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Zymeworks will report full year earnings of ($2.58) per share for the current fiscal year, with EPS estimates ranging from ($3.38) to ($1.83). For the next fiscal year, analysts forecast that the business will report earnings of ($2.80) per share, with EPS estimates ranging from ($3.48) to ($2.12). Zacks’ EPS averages are an average based on a survey of research firms that follow Zymeworks.
Zymeworks (NYSE:ZYME) last announced its earnings results on Friday, August 2nd. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.06). The firm had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $7.25 million. Zymeworks had a negative net margin of 102.78% and a negative return on equity of 24.44%.
A number of brokerages have commented on ZYME. Stifel Nicolaus assumed coverage on shares of Zymeworks in a report on Friday, August 30th. They issued a “buy” rating and a $45.00 price objective on the stock. Raymond James set a $36.00 price objective on shares of Zymeworks and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Barclays raised their target price on Zymeworks from $15.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, August 5th. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a research report on Saturday, August 31st. Finally, Citigroup boosted their price target on Zymeworks from $22.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $34.75.
Large investors have recently modified their holdings of the stock. FMR LLC increased its holdings in Zymeworks by 331.4% in the first quarter. FMR LLC now owns 2,401,897 shares of the company’s stock valued at $38,863,000 after buying an additional 1,845,142 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in Zymeworks by 312.8% during the 2nd quarter. Perceptive Advisors LLC now owns 2,368,890 shares of the company’s stock worth $52,115,000 after buying an additional 1,795,000 shares during the last quarter. Vivo Capital LLC lifted its holdings in Zymeworks by 134.4% during the 2nd quarter. Vivo Capital LLC now owns 1,453,467 shares of the company’s stock worth $31,976,000 after buying an additional 833,333 shares during the last quarter. Camber Capital Management LP grew its position in shares of Zymeworks by 20.0% in the 2nd quarter. Camber Capital Management LP now owns 2,600,000 shares of the company’s stock worth $57,200,000 after acquiring an additional 434,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Zymeworks in the 2nd quarter worth approximately $6,675,000. Institutional investors and hedge funds own 49.95% of the company’s stock.
ZYME traded down $1.90 during trading hours on Thursday, reaching $26.98. 507,554 shares of the stock traded hands, compared to its average volume of 205,173. Zymeworks has a fifty-two week low of $10.72 and a fifty-two week high of $29.75. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -21.41 and a beta of 1.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.07 and a quick ratio of 9.07. The firm’s fifty day simple moving average is $25.22 and its two-hundred day simple moving average is $20.12.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.
Featured Story: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.